Saturday audit & week-ahead playbook

Aman's Global Market Intelligence — 2026-09-26

Generated 08:32 CEST (Europe/Rome) · Data cutoff: Friday 25 Sept. U.S. close, except where noted · Markets are closed; no weekend quote is treated as executable.

NEUTRAL TAPE / RISK-OFF RATES BACKDROP

Friday's equity rebound was real but narrow enough to respect: the S&P 500 rose 0.51%, while the 10-year Treasury finished near 5.16% after touching 5.2297%. Falling oil helped duration, but bond volatility and next week's PCE/jobs data keep the risk budget constrained.

Executive dashboard

S&P 5007,743.41+0.51% Fri

Nasdaq Composite27,068.72+0.48%

Dow51,828.62+0.93%

Russell 20002,837.55+0.07%

VIX14.87−5.11%

U.S. 2Y4.847%Fri 16:04 ET

U.S. 10Y5.155–5.158%intraday high 5.2297%

Dollar index100.97−0.32%

WTI crude$92.41−2.33%

Gold$4,321.20+0.54%

Nikkei 22566,364.20+1.30%

Hang Seng24,510.09−1.01%

STOXX 600638.65+0.35%

DAX / FTSE / MIB+0.56 / +0.14 / +0.63%Friday closes

Prices: Yahoo daily chart API, cross-checked with CNN Markets and Reuters. Yahoo's ^TNX close was 5.184%; Reuters/CNN cash-yield snapshots were 5.158%/5.155%. The dashboard uses the cross-checked cash snapshot and discloses the difference.

1 · Equities defied the bond shock

All three U.S. large-cap indices rose, led by the Dow, despite the 10Y reaching its highest level since 2007. Russell's +0.07% signals limited breadth.

2 · Oil de-escalation offered relief

WTI fell 2.33%; Reuters tied the move to hopes of a U.S.–Iran truce. That is fragile: attacks involving Saudi Arabia remain a supply-tail risk.

3 · AI catalyst, macro hurdle

Microsoft gained 3.66% after new Copilot capabilities, but 5%+ long yields raise the hurdle rate for long-duration AI and quantum stories.

Friday drivers & global read-through

Macro, rates and geopolitics

Rates dominate: Reuters reported the 10Y at 5.158% after 5.2297%; the 30Y reached 5.5319%. The ICE BofA MOVE index rose roughly 30% for the week.
Growth/inflation mix: final Michigan sentiment fell to 48.1 while five-year inflation expectations held 3.4%; durable-goods subcomponents were mixed. This is not a clean soft-landing signal.
Rotation: mega-cap software strength coexisted with nearly flat small caps. High-quality cash flow remains preferable to speculative duration.
Geopolitics: oil relief is headline-sensitive; U.S.–China summit reporting showed symbolism but no material breakthrough on trade, AI or Taiwan.

Asia and Europe

Nikkei +1.30%, KOSPI +0.90%; Hang Seng −1.01%, Shanghai −1.22%, ASX −0.43%: regional dispersion, not a unified risk-on signal.
STOXX 600 +0.35%; DAX +0.56%, FTSE 100 +0.14%, FTSE MIB +0.63%, CAC 40 −0.04%.
Japan's 10Y touched 3.121%, according to Reuters—global term-premium pressure is not solely American.
Saturday mode: there are no reliable U.S. futures to present. Any weekend indication should be treated cautiously until CME reopens Sunday.

Theme dashboards

AI / chips / cloud / power

Selective strength

Leaders: MSFT +3.66%; networking names also featured among Friday gainers, while NVDA closed +0.22% at $225.07.
Verified catalyst: Micron reports fiscal Q4 on Sept. 30. Its SEC-filed Q3 release guided Q4 revenue to $50.0bn ±$1.0bn, ~86% gross margin and non-GAAP EPS $31.00 ±$1.00; expectations are unusually elevated.
Cooling/power: VRT rebounded 3.25% to $253.28 but remains just below its 20-day average ($254.54).
Risk: 5%+ 10Y, customer concentration, export policy, memory cyclicality and capex digestion.

Quantum computing

Venture-like

IONQ +1.11%, RGTI +0.97%, QBTS −0.40%; no broad Friday breakout.
IONQ's recent momentum remains above its 20/50-day averages, but its latest SEC exhibit showed adjusted EBITDA of −$120.3m for Q2 and substantial stock-based compensation/acquisition complexity.
The theme remains acquisition-, roadmap- and sentiment-sensitive. Contract headlines without disclosed economics should not be capitalized as recurring revenue.
Risk: dilution, integration, technical milestones, revenue timing and violent correlated reversals. No short borrow or fee is assumed.

Peptide / metabolic biotech

Clinical catalyst

LLY $1,183.46 (+0.13%) held yesterday's $1,175 confirmation level; detailed retatrutide TRIUMPH-2 data are scheduled at EASD Sept. 30.
Lilly's Phase 3 TRIUMPH-1 release: 80-week efficacy-estimand weight loss was 19.0%/25.9%/28.3% for 4/9/12mg vs 2.2% placebo. GI events and dose-related dysesthesia (up to 12.5%) matter.
VKTX fell another 3.24% to $35.56 after pricing stock at $35 plus convertible notes. It is clinical-stage, with no approved product and substantial binary/dilution risk.
Risk: tolerability, discontinuation, cardiovascular outcomes, access, manufacturing, regulation and competition.

Saturday audit of the 2026-09-25 published calls

Audit uses only the pre-stated levels and Friday's subsequent OHLC; it does not rewrite the thesis with hindsight. These are paper-tracked calls.

Prior call	Friday result	Rule-based audit	Status
VKTX avoid; requalify after 2 closes >$38; risk below $35	$35.56, −3.24%; H/L $39.04/$35.10	Avoid was validated on close. Intraday strength did not produce even one close above $38; the $35 offer price narrowly held.	Validated
NVO avoid until higher low and close >$40	$38.80, +0.47%	Small bounce, still below $40 and well below 20D $43.13 / 50D $45.80.	Intact
VRT avoid; require $250 reclaim then 2 closes >$256	$253.28, +3.25%	First hurdle reclaimed; second not met. The rebound challenges the avoid but does not trigger the stated long confirmation.	Partly challenged
ANET watch; confirm >$207 with breadth/volume	$206.55; intraday $212	Intraday break failed by close. No confirmation.	No trigger
LLY watch; hold $1,175 or post-data higher low	$1,183.46; low $1,160.84	Closed above $1,175 but violated it intraday. Close-based first condition met; clinical binary remains ahead.	Conditional pass
NVDA watch; hold $225 and break $230	$225.07; high $226.94	Held $225 by seven cents, no $230 break. No entry trigger.	No trigger
IONQ watch; require $43–44 retest hold	$45.48; low $44.12	Near-zone retest held, but not inside the full stated zone. Momentum intact; entry evidence only partial.	Partial
MU watch; hold $1,045 and clear $1,100	$1,082.28; high $1,108.72	Intraday clearance failed on close. Pre-earnings no-chase rule remains controlling.	No trigger

Ranked ideas — conditional, paper-tracked

No compelling bullish rank this Saturday. The best setups are watch-only before Wednesday's PCE/Micron/LLY cluster and Friday payrolls. Two avoids are retained; neither is a short recommendation.

#1 Avoid new long — VKTX / Viking Therapeutics

Financing overhang

NASDAQ · Small-cap clinical biotech · Extreme risk · Classification: avoid, not short · Horizon: day and 1–4 weeks · Direction uncertain/gap-prone

Thesis/catalyst: $35 equity pricing and $225m convert supply cap the near-term tape after a high-volume selloff. Evidence: Friday closed $35.56, down 3.24%, after testing $35.10; issuer terms total $500m base proceeds. Counterargument: financing extends runway and VK2735 could differentiate if Phase 3 efficacy/safety succeeds.

Entry / confirmationDo not initiate; requalify only after settlement and two closes above $38 on declining sell volume.

Invalidation / downsideAvoid weakens above $40 with volume. A close below $35 exposes $32–33; gaps can overrun levels.

Clinical / cash pathNo approved product. Phase 3 VANQUISH is ongoing; endpoint, attrition, safety, regulatory and manufacturing outcomes remain binary.

Key risksTrial failure, cash burn, dilution, convert hedging; upside squeeze makes a short dangerous.

Thesis Confidence 91

Risk 95

Opportunity 72

#2 Avoid chasing — MU / Micron

Earnings binary

NASDAQ · Large-cap memory semiconductor · Very high risk · Classification: avoid pre-event chase, not short · Horizon: day through Sept. 30 / 1–4 weeks · Direction uncertain

Thesis/catalyst: Q4 earnings Sept. 30 after close follow a steep run and extraordinary issuer guidance, making “good but not better” a material downside risk. Evidence: $1,082.28, above 20D $994.14 and 50D $941.62; Q3 issuer guide was $50bn revenue and ~86% gross margin. Counterargument: HBM scarcity, strategic agreements and AI demand can drive another beat/raise.

Entry / confirmationNo pre-report chase. Reassess after results; bullish confirmation needs a close above $1,110 with guide-backed volume.

Invalidation / downsideAvoid view weakens on a clean post-report hold above $1,110. Below $1,045 weakens trend; below $1,020 invalidates swing.

FundamentalsQ3 revenue $41.46bn, non-GAAP EPS $25.11 and adjusted FCF $18.3bn; cyclicality and concentration still matter.

Key risksHBM pricing, capex/supply response, customer mix, margins, export policy and large earnings gaps.

Thesis Confidence 86

Risk 94

Opportunity 68

Watchlist — confirmation required

1 · LLY — Clinical watch

Uncertain positive

NYSE · Mega-cap pharma · Medium/high risk · Horizon: 1–4 weeks and 3–12+ months. Thesis: Sept. 30 TRIUMPH-2 detail can reinforce retatrutide's Phase 3 profile. Evidence: $1,183.46 held the prior close trigger; topline met primary endpoint. Counter: valuation, GI events, dysesthesia, discontinuation, no retatrutide approval. Entry: post-data higher low or hold >$1,190. Invalidation/downside: close <$1,145 weakens; <$1,120 invalidates swing. Risks: statistics/estimands, safety, FDA, access, manufacturing, competition.

Confidence 90

Risk 73

Opportunity 78

2 · ANET — AI networking watch

Uncertain positive

NYSE · Large-cap networking · High risk · Horizon: day, 1–4 weeks, 3–12+ months. Thesis: AI Ethernet growth plus positive trend ($206.55 vs 20D $196.58 / 50D $190.23). Counter: Friday's $212 breakout failed; rates and customer concentration. Entry: close >$212 with volume and semiconductor breadth. Invalidation/downside: <$198 weakens, <$190 invalidates tactical case. Risks: capex, competition, exports, valuation, concentration.

Confidence 79

Risk 75

Opportunity 74

3 · NVDA — Quality AI watch

Uncertain positive

NASDAQ · Mega-cap semiconductor · High risk · Horizon: day, 1–4 weeks, 3–12+ months. Thesis: $225.07 remains above 20D $221.75 and 50D $215.98. Counter: no $230 breakout and 5%+ 10Y. Entry: close >$230 with SOX breadth, or controlled $220–223 higher low. Invalidation/downside: <$220 weakens; <$214 invalidates tactical setup. Risks: China/exports, competition, supply, concentration, AI ROI and valuation.

Confidence 85

Risk 79

Opportunity 72

4 · VRT — Recovery watch

Uncertain

NYSE · Large-cap data-center power/cooling · High risk · Horizon: day and 1–4 weeks; 3–12+ months conditional-positive. Thesis: Friday reclaimed $250, but $253.28 remains below 20D $254.54 and 50D $265.95. Counter: secular cooling/power demand can overpower rates. Entry: two closes >$256, stronger >$266 with infrastructure breadth. Invalidation/downside: <$245 weakens, <$240 invalidates recovery. Risks: capex timing, execution, margins, competition, rates.

Confidence 77

Risk 80

Opportunity 66

5 · IONQ — Speculative quantum watch

Extreme risk

NYSE · Mid-cap quantum/acquisition platform · Extreme risk · Horizon: day and 1–4 weeks only · Direction uncertain. Thesis: $45.48 remains above 20D $39.49 / 50D $39.67 and Friday's $44.12 low nearly tested the planned zone. Counter: loss-making, acquisition-heavy economics and undisclosed contract timing. Entry: $43–44 retest/hold or close >$46.55 on strong volume. Invalidation/downside: <$41 weakens, <$39 invalidates momentum. Risks: dilution, integration, roadmap, revenue recognition and severe reversals.

Confidence 86

Risk 97

Opportunity 65

Changes versus Friday's report

Regime upgraded one notch: from risk-off to neutral tape/risk-off rates after positive U.S./European closes and oil's decline; 5.16% 10Y prevents risk-on.
VKTX avoid validated: another −3.24%; it stays #1 but Friday's test of $35.10 makes the offer price the immediate fulcrum.
VRT improved: +3.25% reclaimed $250, moving from avoid to recovery watch; it still lacks the two >$256 closes previously required.
LLY condition partly met: closed above $1,175; it leads the watchlist into EASD, not a pre-data buy.
MU elevated to explicit avoid-chase: its $1,108.72 intraday breakout failed and Wednesday earnings create a high-expectations binary.
No bullish entry added: ANET, NVDA, IONQ and MU all failed at least one pre-declared confirmation condition.

Important 7–30 day catalysts

Sept. 28 — Dallas Fed manufacturing survey, 10:30 ET.

Sept. 28–Oct. 2 — EASD, Milan: metabolic/peptide presentations; distinguish conference detail from new endpoints.

Sept. 29 — August JOLTS and Consumer Confidence, 10:00 ET. Labor tightness is a rates catalyst.

Sept. 30, 08:15–08:30 ET — ADP; Q2 GDP third estimate; August personal income/outlays and PCE. BEA schedule.

Sept. 30, 08:30 CEST — Lilly TRIUMPH-2 retatrutide detail at EASD: inspect confidence intervals, estimands, discontinuations and dysesthesia/GI safety.

Sept. 30 after U.S. close — Micron fiscal Q4; issuer call 2:30 p.m. MT. Micron IR.

Oct. 1 — ISM manufacturing; prices paid matters for the yield shock.

Oct. 2, 08:30 ET — September Employment Situation. BLS.

Oct. 6 — August U.S. international trade.

Oct. 27–28 — FOMC meeting. Fed calendar.

Q4, date undisclosed — expected CagriSema regulatory action; no exact FDA date is asserted.

Bottom line by horizon

Day trade

Plan: wait for Monday cash confirmation. Favor ANET/NVDA only through stated breakouts; do not chase MU or LLY into binaries. Biggest risk: Middle East oil gap or renewed yield spike. Invalidation: 10Y sustainably below 5.10% with broad equity participation would invalidate the defensive stance.

1–4 week swing

Plan: smaller positions, explicit stops, cash reserve. LLY is the best evidence-backed catalyst watch; VRT requires trend repair. Biggest risk: PCE/jobs reprice the Fed higher. Invalidation: S&P higher low plus falling MOVE/10Y and small-cap confirmation.

3–12+ month investment

Plan: stage cash-generative AI/networking/power and validated metabolic leaders; treat quantum and clinical-stage biotech as venture-like. Biggest risk: earnings/cash-flow growth fails to clear the discount rate. Invalidation: estimate cuts, roadmap slippage, clinical failure or financing stress.

Data quality & methodology

Controls

Research included live Yahoo chart/API pulls, Reuters/CNN market reporting, BLS/BEA/Fed/NY Fed calendars, company IR and SEC filings—well above five meaningful retrievals.
Friday OHLC, 20/50-session averages and changes were computed from Yahoo daily observations; headline levels were cross-checked with CNN and Reuters.
Company/trial claims use issuer or regulator sources. No rumor, analyst target, invented estimate, borrow availability or fee supports an idea.
Confidence measures evidence quality, not guaranteed outcome probability. Risk rises with danger; Opportunity reflects setup quality after risk.

Known limitations

Markets are closed Saturday; Friday closes are not live weekend quotes. Futures are intentionally omitted until a reliable session opens.
Yahoo's ^TNX convention printed 5.184%, while cash snapshots were 5.155–5.158%; both are disclosed rather than silently mixed.
A requested SEC URL initially returned NoSuchKey; SEC search located the valid IonQ filing/exhibit. Three web searches later hit a vendor rate limit; primary calendars/IR and accessible alternatives supplied the required facts, so no material field is declared unavailable.
Clinical releases are sponsor-reported and not substitutes for full peer review or FDA assessment. Conference programs can change.

Sources

Reuters global markets, Sept. 25 — rates, oil, global equities, geopolitics and timestamps.
CNN Markets — U.S./global closes, cash Treasury snapshots and commodities.
Yahoo Markets/chart API — daily OHLC, volume and derived moving averages retrieved 08:31–08:32 CEST.
BLS schedule; BEA schedule; NY Fed calendar; FOMC calendar.
Micron Q3 SEC exhibit; Micron Q4 event notice.
Lilly TRIUMPH-1 Phase 3 release; Lilly TRIUMPH-2 release.
Viking financing terms.
IonQ Q2 SEC exhibit.